Scott Rocklage is one of 5AM Ventures’ Managing Partners. He joined the company in 2003 as a partner and later promoted in 2004. With over 20 years of experience in healthcare management and strategic leadership, the Chemistry Ph.D. holder led the company to develop new drugs (Omniscan™, Cubicin®, and Teslascan®) that were later approved by the FDA.
Dr. Scott Rocklage has previously worked at Cubist Pharmaceuticals (CEO and Chairman), Nycomed Salutar (President and CEO), and Nycomed Interventional (Chairman, President, and CEO). He had also held several Research and Development positions when he was working at Salutar and Catalytica.
Presently, Dr. Rocklage serves as the Board Chairman of Semprus, Achaogen, and Relypsa. Furthermore, he is a board member of Pulmatrix and Variation, WaveRx, and Whitehead Institute. Dr. Rocklage received his B.S. (Chemistry) from University of California-Berkeley. He later attended Massachusetts Institute of Technology for his Chemistry Ph.D. Today, he is based in Waltham, Ma.
5AM Ventures is a successful capital company, which aims to build future generation life science firms with the ability to distribute high profits to its investors. It supports companies that aim to provide solutions to healthcare needs by providing innovations in medicine and science. Furthermore, the venture’s portfolio firms spearhead new methods to diagnose, prevent, and offer treatment to various medical conditions.
Board members are also actively involved in the company’s operations as they take up short-term responsibility roles. On the other hand, the company is accountable to all its investors, which allows them to appreciate the amount of work put in to ensure good returns on their investment. 5AM Ventures has centers in the cities of Boston, Massachusetts, and San Francisco, California. It also works with several portfolio companies within the healthcare industry.
Practical Approaches that Define the Success Behind 5AM Ventures
A hands-on approach to company building: 5AM works diligently with portfolio firms in their early stages by carrying out short-term operating duties and offering practical guidance throughout their life.
Teamwork, networking, and broad operational skills: 5AM is capable of recognizing the finest scientists in leading fields, work with specialized entrepreneurs, and co-invest with value-added partners at prominent life science companies.
Capital productivity and reduced realization time: 5AM’s prospect involves producing high returns in three to five years.